Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109234 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
NCT05109234 is a Phase 3 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 84 participants.
The verdict
NCT05109234, a Phase 3 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
Interventions
- DRUG Brivaracetam Film-coated tablet
- DRUG Brivaracetam oral solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2025-03-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109234
The ClinicalTrials.gov registry entry for NCT05109234 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Brivaracetam Film-coated tablet is the first listed.
NCT05109234 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05109234 about?
NCT05109234 is a clinical study titled "A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy". The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
What is the current status of trial NCT05109234?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2022-03-30. Estimated completion is 2025-03-18.
What interventions are being tested in trial NCT05109234?
The interventions under investigation include: Brivaracetam Film-coated tablet (DRUG), Brivaracetam oral solution (DRUG).
Who is sponsoring clinical trial NCT05109234?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.